GoodRx appoints Scott Wagner as new board director
GoodRx Holdings, Inc. (NASDAQ:GDRX), a leader in consumer-focused digital healthcare platforms with impressive gross profit margins of 94%, announced the appointment of Scott Wagner as a Class II ...
Direct Marketing News11d
GoodRx launches new experience for pets
Explore GoodRx's innovative new service designed to make pet care more affordable and accessible for pet owners.
Seeking Alpha18d
GoodRx: A Business In Transition, But It Has Likely Reached Its Low (Rating Upgrade)
Shares of GoodRx have fallen ~20% over the past year. Amid hopes for growth via direct relationships with pharmaceutical manufacturers, the company may have hit a near-term bottom. GDRX returned ...
GoodRx任命Scott Wagner为新董事会成员
GoodRx Holdings, Inc. (NASDAQ: GDRX )是消费者数字医疗平台的领导者，拥有令人印象深刻的94%毛利率。该公司近日宣布任命Scott Wagner为II类董事和董事会联席主席。根据最近的SEC文件，这一任命是在Wagner于2023年4月至2025年1月担任临时CEO之后做出的。根据 InvestingPro ...
Scott Wagner appointed Co-Chair of GoodRx Board
SANTA MONICA, Calif. - GoodRx Holdings, Inc. (NASDAQ:GDRX), a leading U.S. prescription savings platform, announced the appointment of Scott Wagner as Co-Chair of its Board of Directors, effective ...
ConsumerAffairs12d
GoodRx for Pets offers prescription discounts for pets
Pet owners now have a new online resource that can help them save money. GoodRx, a company known for offering consumers ...
Scott Wagner被任命为GoodRx董事会联席主席
加利福尼亚州圣莫尼卡 - 美国领先的处方药节省平台GoodRx Holdings, Inc. (NASDAQ: GDRX )宣布，Scott Wagner将于2025年1月21日起担任董事会联席主席。Wagner此前从2023年4月起担任公司临时CEO，直至最近被任命为新职务。他为这一角色带来了超过25年的高管领导经验。根据 InvestingPro ...
Scott Wagner Joins GoodRx Board of Directors
GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced that Scott Wagner has joined its Board of ...
GoodRx price target lowered to $4.25 from $4.50 at BofA
BofA lowered the firm’s price target on GoodRx (GDRX) to $4.25 from $4.50 and keeps an Underperform rating on the shares after the company ...
GoodRx price target lowered to $6.25 from $7 at Citi
Citi analyst Daniel Grosslight lowered the firm’s price target on GoodRx (GDRX) to $6.25 from $7 and keeps a Buy rating on the shares as part ...
Fox News25d
19 drug approvals in 2024 that had 'big clinical impact,' according to GoodRx
In a disclaimer, GoodRx noted that the list was created by prioritizing "first-in-class medications and vaccines that are expected to have a significant impact on human health." "This was defined ...
GoodRx (NASDAQ:GDRX) Shares Down 8.4% After Analyst Downgrade
GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) dropped 8.4% during trading on Monday after Citigroup lowered their price target on the stock from $7.00 to $6.25. Citigroup currently has a buy ...